survival and late effects: survival and late effects
Study summary
To describe the natural history of peripheral neuroblastic tumour presenting with SCI and evaluate the combined effects of different risk factors on the eventual neurologic and orthopaedic outcomes
Eligibility
Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria:
* Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse/progression)
* No previous chemotherapy, except steroids, in the last 6 months
* Age \<18 years
* Minimal planned follow-up of 5 years
* Parent/patient written informed consent (Appendix 1(A,B,C))
Exclusion Criteria:
* Invasion of intervertebral foramina only
Primary outcome measure(s)
prevalence of neurologic consequences — for 5 years American Spinal Injury Association ASIA impairment scale
prevalence of orthopedic consequences — for 5 years using Common Terminology Criteria for Adverse Events v. 4.0
prevalence of pain — for 5 years using Face, Legs, Activity, Cry, Consolability scale (FLACC scale)
Trial sites (1)
Facility
City
Region
Status
Istituto Giannina Gaslini
Genova
Italy
Recruiting
More Associazione Italiana Ematologia Oncologia Pediatrica trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
